JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets clinical trials

An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors (NIRADO)

This study is testing two medicines, JEMPERLI and Zejula, together to see if they can help people with certain types of cancer. Doctors want to know how well this combination shrinks tumors and if it's safe to use. It's a next step in finding new cancer treatments.